- Home
- Primary Care
- BTK Inhibitors in the Management of Generalized Myasthenia Gravis

1d3 min read
Medical Article
Introduction Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue. It primarily results from autoantibodies that target components of the neuromuscular junction, particularly the acetylcholine receptor (AChR), leading to impaired signal transmission between nerves and muscles

BTK Inhibitors in the Management of Generalized Myasthenia Gravis
Similar Content

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes

Young Girl Presented with Irritability and Abnormal Behavior
2249 Reached11 Comments5 Likes

FOURIER Trial: Efficacy of Evolocumab in Managing Cardiovascular Events
563 Reached3 Comments